StockData
Lexaria Bioscience Corp. logo

Lexaria Bioscience Corp. (LEXX) stock

LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
Financials through Q3 FY2026, quarter ended May 31, 2026Last filing: 10-Q on Jul 13, 2026Score 8/30
$4.44+0.26 (+6.22%)

Close on Nov 13, 2026Market cap $110.06MP/E –Yield –

Lexaria Bioscience gross margin

Gross margin is gross profit as a percentage of revenue.

Lexaria Bioscience's gross margin for the twelve months ending May 31, 2026 was 100.0%. For fiscal 2025 it was 99.6%, against 99.0% the year before. The highest annual figure on record is 99.6% in fiscal 2025.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Aug 31, 202599.6%+0.7
FY2024Aug 31, 202499.0%+12.9
FY2023Aug 31, 202386.1%+14.2
FY2022Aug 31, 202271.9%−3.9
FY2021Aug 31, 202175.7%+7.3
FY2020Aug 31, 202068.4%−21.3
FY2019Aug 31, 201989.7%−4.5
FY2018Aug 31, 201894.2%+40.9
FY2017Aug 31, 201753.3%+65.3
FY2016Aug 31, 2016-12.0%+91.2
FY2015Aug 31, 2015-103.3%–

Quarterly gross margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q2 FY2026CQ1 2026Feb 28, 2026100.0%+1.5
Q4 FY2025CQ3 2025Aug 31, 2025100.0%+0.0
Q3 FY2025CQ2 2025May 31, 2025100.0%+0.0
Q2 FY2025CQ1 2025Feb 28, 2025100.0%+0.0
Q1 FY2025CQ4 2024Nov 30, 202498.5%+1.7
Q4 FY2024CQ3 2024Aug 31, 2024100.0%+0.0
Q3 FY2024CQ2 2024May 31, 2024100.0%+16.4
Q2 FY2024CQ1 2024Feb 29, 2024100.0%+14.8
Q1 FY2024CQ4 2023Nov 30, 202396.8%+13.0
Q4 FY2023CQ3 2023Aug 31, 2023100.0%+37.1
Q3 FY2023CQ2 2023May 31, 202383.6%+2.3
Q2 FY2023CQ1 2023Feb 28, 202385.2%+6.1
Q1 FY2023CQ4 2022Nov 30, 202283.8%+24.0
Q4 FY2022CQ3 2022Aug 31, 202262.9%+28.4
Q3 FY2022CQ2 2022May 31, 202281.3%+10.7
Q2 FY2022CQ1 2022Feb 28, 202279.2%−4.9
Q1 FY2022CQ4 2021Nov 30, 202159.9%−18.3
Q4 FY2021CQ3 2021Aug 31, 202134.5%−45.0
Q3 FY2021CQ2 2021May 31, 202170.6%+26.4
Q2 FY2021CQ1 2021Feb 28, 202184.1%+138.8
Q1 FY2021CQ4 2020Nov 30, 202078.2%+54.2
Q4 FY2020CQ3 2020Aug 31, 202079.5%−8.5
Q3 FY2020CQ2 2020May 31, 202044.2%−50.6
Q2 FY2020CQ1 2020Feb 29, 2020-54.7%−137.2
Q1 FY2020CQ4 2019Nov 30, 201924.0%−66.3
Q4 FY2019CQ3 2019Aug 31, 201988.1%−8.9
Q3 FY2019CQ2 2019May 31, 201994.8%−3.4
Q2 FY2019CQ1 2019Feb 28, 201982.5%−9.6
Q1 FY2019CQ4 2018Nov 30, 201890.3%+15.0
Q4 FY2018CQ3 2018Aug 31, 201896.9%+35.2
Q3 FY2018CQ2 2018May 31, 201898.3%+29.7
Q2 FY2018CQ1 2018Feb 28, 201892.0%+110.0
Q1 FY2018CQ4 2017Nov 30, 201775.2%−15.1
Q4 FY2017CQ3 2017Aug 31, 201761.7%−6.9
Q3 FY2017CQ2 2017May 31, 201768.6%–
Q2 FY2017CQ1 2017Feb 28, 2017-18.0%–
Q1 FY2017CQ4 2016Nov 30, 201690.4%–
Q4 FY2016CQ3 2016Aug 31, 201668.6%–

More Lexaria Bioscience figures

See a number that looks wrong?